Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H21N3O.C6H8O7 |
| Molecular Weight | 391.4168 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)C(=O)N1CCN(C)CC1
InChI
InChIKey=PGNKBEARDDELNB-UHFFFAOYSA-N
InChI=1S/C10H21N3O.C6H8O7/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-9H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DescriptionCurator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf
Curator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf
Diethylcarbamazine is used in humans, dogs and cats for the treatment of parasitic infections, including pulmonary eosinophilia, loiasis, and lymphatic filariasis. The exact mechanism of its action is unknown, however some studies showed the involvment of inducible nitric-oxide synthase and the cyclooxygenase pathway. Although there is no information on whether the drug is marketed in the USA and Europe, it is currently used in India.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
|||
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
|||
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
637 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5840 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
7220 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
Other AEs: Fever, Pruritus... Other AEs: Fever (63.6%) Sources: Pruritus (9.1%) Giddiness (9.1%) Joint ache (9.1%) |
2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
Other AEs: Fever, Nausea... Other AEs: Fever Sources: Nausea (27.3%) Vomiting (18.2%) Abdominal discomfort (9.1%) |
50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Sources: Papular urticarial eruption (30%) Proteinuria (10%) Visual field constriction (20%) Optic nerve pallor (10%) Corneal opacity (90%) Anterior uveitis (10%) Chorioretinitis (10%) |
300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Sources: Papular urticarial eruption (70%) Proteinuria (30%) Visual field constriction (10%) Optic nerve pallor (20%) Corneal opacity (80%) Anterior uveitis (30%) Chorioretinitis (30%) |
6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
Other AEs: Fatigue, Nausea... Other AEs: Fatigue (grade 2, 5%) Sources: Nausea (grade 2, 2%) Vomiting (grade 2, 2%) Joint pain (grade 2, 2%) Eye swelling (grade 2, 2%) Rash (grade 2, 2%) Dyspnea (grade 2, 2%) |
8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
Other AEs: Fever, Headache... Other AEs: Fever (69%) Sources: Headache (65%) Vertigo (57%) Malaise (49%) Chills (45%) Joint pain (40%) Abdominal pain (37%) Chest pain (33%) Nausea (28%) Neck pain (24%) Vomiting (16%) Muscular pain (14%) Lymph node tenderness (38%) Epididymal tenderness (34%) Nodule (15%) Tinnitus (8%) Convulsion (2%) Eruption (<1%) Shock (<1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Fever | 63.6% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
| Giddiness | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
| Joint ache | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
| Pruritus | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
| Fever | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
|
| Vomiting | 18.2% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
| Nausea | 27.3% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
| Abdominal discomfort | 9.1% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
| Anterior uveitis | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Chorioretinitis | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Optic nerve pallor | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Proteinuria | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Lymphadenopathy | 100% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Visual field constriction | 20% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Papular urticarial eruption | 30% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Corneal opacity | 90% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Visual field constriction | 10% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Lymphadenopathy | 100% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Optic nerve pallor | 20% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Anterior uveitis | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Chorioretinitis | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Proteinuria | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Papular urticarial eruption | 70% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Corneal opacity | 80% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Dyspnea | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Eye swelling | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Joint pain | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Nausea | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Rash | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Vomiting | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Fatigue | grade 2, 5% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Muscular pain | 14% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Nodule | 15% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Vomiting | 16% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Convulsion | 2% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Neck pain | 24% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Nausea | 28% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Chest pain | 33% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Epididymal tenderness | 34% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Abdominal pain | 37% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Lymph node tenderness | 38% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Joint pain | 40% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Chills | 45% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Malaise | 49% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Vertigo | 57% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Headache | 65% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Fever | 69% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Tinnitus | 8% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Eruption | <1% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Shock | <1% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [Activation >10 uM] | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes [Inhibition 10 uM] | ||||
| yes [Inhibition 10 uM] | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| likely | ||||
| likely | ||||
| no | no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. |
|||
| no | no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A brief introduction to the research achievement on the strategy and technical measures for interrupting the transmission of lymphatic filariasis in China. | 2001 |
|
| Compliance with the mass chemotherapy program for lymphatic filariasis. | 2001 Dec |
|
| Lymphatic filariasis in kenya since 1910, and the prospects for its elimination: a review. | 2001 Nov |
|
| Anthelmintics: a review. | 2001 Oct-Dec |
|
| Mass DEC campaign for filariasis in a hyper endemic district of West Bengal. | 2001 Sep |
|
| [Toxocariasis in Poznan region, Poland, in years 1990-2000]. | 2002 |
|
| [Technical measures of filariasis elimination in Tengzhou City]. | 2002 |
|
| Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation. | 2002 |
|
| Subconjunctival Loa Loa worm: case report. | 2002 |
|
| The impact of single-dose diethylcarbamazine treatment of bancroftian filariasis in a low-endemicity setting in Egypt. | 2002 Aug |
|
| Modelling the epidemiology, transmission and control of lymphatic filariasis. | 2002 Dec |
|
| Use of floating layers of polystyrene beads to control populations of the filaria vector Culex quinquefasciatus. | 2002 Dec |
|
| Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis. | 2002 Dec |
|
| Operational issues in the control of the vectors of Brugia. | 2002 Dec |
|
| Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities. | 2002 Dec |
|
| Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods. | 2002 Dec |
|
| Bancroftian filariasis: clinical parasitologic and serologic evaluation after 4 years applying two antifilarial regimens. | 2002 Dec |
|
| Major progress toward eliminating lymphatic filariasis. | 2002 Dec 5 |
|
| Mass treatment to eliminate filariasis in Papua New Guinea. | 2002 Dec 5 |
|
| New goals set for filariasis elimination in India. | 2002 Jul |
|
| Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India. | 2002 Jun |
|
| Mass drug administration to treat lymphatic filariasis. | 2002 Jun 1 |
|
| Young male with pancytopenia: an unusual cause. | 2002 May |
|
| Case 1-2002: Loa loa. | 2002 May 30 |
|
| Electron microscopic and molecular identification of Wolbachia endosymbionts from Onchocerca lupi: implications for therapy. | 2002 May 30 |
|
| [Asthenoscopic problems with a subconjunctival worm]. | 2002 Nov |
|
| Neoplastic change in Onchocerca volvulus and its relation to ivermectin treatment. | 2002 Nov |
|
| Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. | 2002 Nov |
|
| Prevalence of diurnally subperiodic bancroftian filariasis among the Nicobarese in Andaman and Nicobar Islands, India: effect of age and gender. | 2002 Nov |
|
| Targeting of children in filariasis mass drug administration. | 2002 Nov 2 |
|
| Case report: intraocular localization of Mansonella perstans in a patient from south Chad. | 2002 Nov-Dec |
|
| Red blood cell antioxidant levels in Wuchereria bancrofti infection. | 2002 Oct |
|
| Microfilaria in a thyroid nodule which resolved on treatment. | 2002 Oct |
|
| Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae. | 2002 Oct |
|
| The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. | 2002 Sep |
|
| The influence of the mass administration of diethylcarbamazine, alone or with albendazole, on the prevalence of filarial antigenaemia. | 2002 Sep |
|
| The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination. | 2002 Sep |
|
| Efficacy and sustainability of a footcare programme in preventing acute attacks of adenolymphangitis in Brugian filariasis. | 2002 Sep |
|
| Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials. | 2002 Sep 30 |
|
| Targeting apoptotic signalling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage. | 2003 |
|
| A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. | 2003 |
|
| Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. | 2003 Apr |
|
| Long-term population migration: an important aspect to be considered during mass drug administration for elimination of lymphatic filariasis. | 2003 Apr |
|
| Long-term follow-up of treatment with diethylcarbamazine on anti-filarial IgG4: dosage, compliance, and differential patterns in adults and children. | 2003 Jan |
|
| Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection. | 2003 Jan 1 |
|
| Relationships between Wuchereria bancrofti microfilaria counts in human blood and parasite uptake and maturation in Culex pipiens, with observations on the effects of diethylcarbamazine treatment on these parameters. | 2003 Mar |
|
| Setaria cervi: in vitro released collagenases and their inhibition by Wuchereria bancrofti infected sera. | 2003 Mar |
|
| Strategic options for global lymphatic filariasis elimination. | 2003 May |
|
| Ensuring supplies of quality diethylcarbamazine citrate (DEC). | 2003 May |
|
| Lymphatic filariasis. | 2003 May 16 |
Sample Use Guides
Lymphatic filariasis: 6 mg/kg daily for 12 days administered orally, preferably in divided doses after meals (W. bancrofti infection); 3-6 mg/kg daily for 6-12 days administered orally, preferably in divided doses after meals (B. malayi and B. timori infections). Tropical pulmonary eosinophilia: a dose of 8 mg/kg daily for 14 days repeated, as necessary, if symptoms return.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 520.622B
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
||
|
CFR |
21 CFR 520.622
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
||
|
CFR |
21 CFR 520.622A
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
||
|
CFR |
21 CFR 520.622C
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID4045555
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
DBSALT000975
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
80513
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
OS1Z389K8S
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
C65379
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
216-696-6
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
1193006
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
m4398
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL684
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
1642-54-2
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
DIETHYLCARBAMAZINE DIHYDROGEN CITRATE
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | Description: A white, crystalline powder; odourless or almost odourless.Solubility: Very soluble in water; soluble in 35 parts of ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Filaricide.Storage: Diethylcarbamazine dihydrogen citrate should be kept in a tightly closed container, protected from light.Additional information: Diethylcarbamazine dihydrogen citrate is hygroscopic; it has an acid and bitter taste. Even in the absenceof light, Diethylcarbamazine dihydrogen citrate is gradually degraded on exposure to a humid atmosphere, the decompositionbeing faster at higher temperatures.Definition: Diethylcarbamazine dihydrogen citrate contains not less than 98.0% and not more than 101.0% of C10H21N3O,C6H8O7, calculated with reference to the anhydrous substance. | ||
|
SUB01686MIG
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
203175
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
OS1Z389K8S
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
100000087926
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
6421
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
15432
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
